No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.

• Anixa Biosciences, Inc.
• Black Diamond Therapeutics, Inc.
• Formosa Pharmaceuticals, Inc.
• Sagittarius Life Science Corp
• CANbridge Pharmaceuticals Inc.
• Nautilus Biotechnolgy, Inc.
• 4basebio PLC
• Coya Therapeutics, Inc.